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Heterozygous Mutations in TREX1 Cause Familial Chilblain Lupus
and Dominant Aicardi-Goutie`res Syndrome
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TREX1 constitutes the major 3′r5′ DNA exonuclease activity measured in mammalian cells. Recently, biallelic mutations
in TREX1 have been shown to cause Aicardi-Goutie`res syndrome at the AGS1 locus. Interestingly, Aicardi-Goutie`res
syndrome shows overlap with systemic lupus erythematosus at both clinical and pathological levels. Here, we report a
heterozygous TREX1 mutation causing familial chilblain lupus. Additionally, we describe a de novo heterozygous mu-
tation, affecting a critical catalytic residue in TREX1, that results in typical Aicardi-Goutie`res syndrome.
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TREX1 (GenBank accession numbers AAK07616 and NM_
033627) represents the major DNA-specific 3′r5′ exonu-
clease activity measured in mammalian cells.1 The non-
processive autonomous mode of action of TREX1 suggested
a possible proofreading role during lagging-strand DNA
synthesis or a gap-filling role during DNA repair.2 How-
ever, Trex1-null mice show no increase in spontaneous
mutation frequency or cancer incidence.3 Rather, they de-
velop an inflammatory myocarditis with progressive di-
lated cardiomyopathy, indicating a previously unrecog-
nized cellular role for the enzyme. Of note, although there
was a dramatically increased morbidity of Trex1-null mice
postweaning, these mice did not exhibit any obvious neu-
rological defect.
Aicardi-Goutie`res syndrome (AGS [MIM 225750]) is a
genetically determined encephalopathy characterized by
calcification of the basal ganglia and white matter, demye-
lination, and raised levels of lymphocytes in the cerebro-
spinal fluid.4 Neurological dysfunction becomes clinically
apparent in infancy and manifests as progressive micro-
cephaly, spasticity, dystonia, and psychomotor retardation.
We identified the AGS1 locus elsewhere,5 and we recently
demonstrated that biallelic mutations in TREX1 result in
AGS at the AGS1 locus6 and that mutations in genes en-
coding the three nonallelic components of the RNASEH2
protein complex also cause AGS.7
We and others have drawn attention to features sug-
gesting immune dysfunction in AGS, and a number of
reports have specifically highlighted the phenotypic over-
lap of AGS with the autoimmune syndrome systemic lu-
pus erythematosus (SLE).8–12 Recently, Lee-Kirsch et al.13
described a family segregating a monogenic form of cuta-
neous lupus in which affected individuals presented with
ulcerating lesions of the skin in acral locations, features
highly reminiscent of the chilblains seen in some children
with AGS.14 They mapped this disease, termed “familial
chilblain lupus” (FCL [MIM 610448]), to the AGS1 critical
interval and drew attention to the phenotypic overlap
with AGS.
Here, we describe a family with FCL that segregates a
heterozygous pathogenic mutation in TREX1 as a domi-
nant trait. Additionally, we report a child with typical AGS
whose condition results from a de novo heterozygous mu-
tation in TREX1. These novel findings show that certain
rare mutations in the TREX1 gene can result in a dominant
phenotype with symptoms of FCL and/or AGS.
We ascertained a nonconsanguineous Bangladeshi fam-
ily in which two brothers and a sister demonstrate features
of FCL (fig. 1 and table 1). Their father had been similarly
affected throughout his life but was not available for study.
There are three siblings without symptoms, one of whom
was also studied, and their mother is healthy, with no
features of disease in her 8th decade. The onset of the
disease was in early childhood. Affected individuals pre-
sented with painful bluish-red swelling of the skin affect-
ing mainly the fingers, toes, ears, helices, and, occasion-
ally, the nose. The lesions were induced by cold temper-
atures and were significantly worse in the winter months.
These lesions could ulcerate; in the two affected males,
the ulcerations led to a loss of ear cartilage and destruction
of the proximal interphalangeal (PIP) joints and distal toes
(fig. 2). Ulcerative lesions healed but left areas of atrophic
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Figure 1. Pedigree of the nonconsanguineous family showing
vertical transmission of FCL (affected individuals are indicated by
blackened symbols). Note that individual II:4 is clinically asymp-
tomatic but carries the familial disease-causing mutation.
Table 1. Summary of Clinical Features in the FCL-Affected Family
Subject and Clinical Description Laboratory Findings Comments
II:3:
Presentation as an infant. Lesions affecting hands and feet, especially over
PIP joints, sides of fingers, and ends of toes. Active disease associated
with extension of swelling and redness along the digit, resulting in func-
tional loss with pain for the duration of the swelling. No involvement of
ears or nose. Large joint arthralgias, mainly of the knees, without swell-
ing. In the quiescent periods, she is left with scarred, atrophic, and hy-
popigmented lesions.
Variable antinuclear antibodies, ranging from nor-
mal to 1:1,000 (homogeneous). Persistently
raised ESR (20–40; normal !3). Negative ex-
tractable nuclear antigens (Sm, RNP, SCl70,
Jo1, PM1, Ro, and La), anti–double-stranded
DNA (anti-dsDNA), pANCA/cANCA, cardiolipin,
rheumatoid factor, hepatitis C, cryoglobulins,
and cryofibrinogen. Normal C3 and C4.
Treatment with hydroxychoro-
quine and sulfasalazine not
tolerated. No response to
prednisolone or iloprost.
II:5:
Initial presentation at age 4 years, with recurrent cold fingers and toes.
Digits swelled in cold weather, becoming red and “peeled.” Received di-
agnosis of chilblains. Continued episodes associated with pain and tissue
infarcts and ulceration involving the digits, tip of the nose, and pinnae.
Eventual “autoamputation” of the 4th right toe. Two episodes of frank
knee swelling and effusion. He is left with marked tapering of the digits,
with tightening of the skin and prominence of the PIP and distal inter-
phalangeal joints.
Antinuclear antibodies 1:100 (homogeneous) on
one occasion. Left synovial knee aspirate
showed 13,000 white cells/mm3. Negative ex-
tractable nuclear antigens, anti-dsDNA, pANCA/
cANCA, cardiolipin, rheumatoid factor, cry-
oglobulins, cryofibrinogen, C3, and C4.
X-ray of hands demonstrated
resorption of terminal pha-
langes of all toes, left little
and ring fingers, and right
little finger, with subluxa-
tion of the PIP joint of the
left little finger. No re-
sponse to nifedipine or
epoprostenol.
II:6:
Presentation at age 4 years. Features similar to those of subject II:5, al-
though he has not experienced episodes of large joint swelling.
No data available.
and hypopigmented skin. There was no history of pho-
tosensitivity, fever, weight loss, immune deficiency, or ma-
lignancy. There was no associated Raynaud phenomenon,
and there was no response to nifedipine or to a 3-d in-
fusion of the prostacyclin analog iloprost. Treatment with
prednisolone, sulfasalazine, and hydroxychoroquine was
also unhelpful. One patient experienced swelling of the
knee on two occasions, and joint aspiration demonstrated
a sterile effusion consistent with a seronegative inflamma-
tory athropathy. Skin biopsy was never performed. There
was no evidence of cryoglobulinemia, cryofibrinogene-
mia, cold agglutinins, or hepatitis C. Tests for rheumatoid
factor, anticardiolipin antibodies, and extractable nuclear
antigens were consistently negative. However, antinuclear
antibody titres were intermittently raised, and one patient
exhibited persistently elevated erythrocyte-sedimentation
rate (ESR).
Sequencing of the single-exon TREX1 gene revealed that
all three affected individuals carried a c.375dupT and a
c.50TrC transition that resulted in the replacement of a
phenylalanine with a serine at position 17 (p.F17S). Clon-
ing into a pGEM vector system demonstrated that these
variants were present on different alleles. The mother is
heterozygous for the c.50TrC change only. Sequencing of
the RNASEH2A, -B, and -C genes was normal. The TREX1
c.375dupT is predicted to result in a truncated protein
missing the last 188 aa. Despite its position within the
EXO I domain, one of three sequence motifs containing
four acidic residues participating in the coordination of
divalent metal ions necessary for catalysis—the phenyl-
alanine at position 17—is not conserved in mouse Trex1
or the related human TREX2.2,15 Moreover, the purified
recombinant TREX1 F17S/F17S homodimer exhibited nor-
mal 3′r5′ exonuclease activity, indicating that this amino
acid change does not adversely affect the catalytic activity
of the recombinant TREX1 when measured in vitro (table
2).16 Thus, although the F17S change was not seen in a
panel of 50 Asian control individuals, these data—to-
gether with the history of chilblains in the father, who
must harbor the c.375dupT—led us to conclude that c.50TC
is a rare polymorphism. Interestingly, one sister (II:4) was
unaffected on clinical examination but carried the same
molecular changes seen in her affected siblings. Further
testing in this asymptomatic woman revealed a significant
lymphopenia ( /liter; normal 1.5– /li-9 91.16# 10 4.0# 10
ter) and raised ESR (23 mm/1st hour; normal 0–7 mm/1st
hour), suggesting subclinical penetrance. Results of serum
interferon alpha (IFN-a) testing in one symptomatic pa-
tient were normal.
Lymphoblastoid cell lines were established from af-
fected individuals, and TREX1 exonuclease activity in cell
extracts was measured, as described elsewhere, with use
of a polydeoxynucleotide substrate.3 Extracts of control
lymphoblastoid cell lines exhibited readily detected TREX1
activity. In contrast, lymphoblastoid cell lines derived from
all three patients with FCL showed exonuclease activity
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Figure 2. Skin features observed in FCL-affected family. The lesions are quiescent at present, but there are residual areas of atrophic
and hypopigmented skin. Previous ulcerations have led to a loss of ear cartilage and destruction of the PIP joints and distal toes. Note
the tapering of the fingers, with tight, shiny skin.
Table 2. TREX1 Enzyme Activity of
Wild-Type and Recombinant F17S/F17S
Homodimers
Dimer Activitya
Relative
Activity
Wild-type/wild-type 2.8 1
F17S/F17S 3.5 1.2
a Measured as fmol nucleotides released per s.
Figure 3. TREX1 exonuclease activity. Cell-free protein extracts
were assayed for 3′ DNA exonuclease activity with a 3′ labeled
poly(dA) substrate after partial purification by column chroma-
tography on single-stranded DNA cellulose. GM0558 is a normal
lymphoblastoid control. F39A is a lymphoblastoid cell line from a
child with biallelic mutations in TREX1.
with a consistently marked reduction, to ∼15%–35% that
of a normal lymphoblastoid control, but clearly more than
seen in an AGS cell line6 with biallelic inactivating TREX1
mutations (fig. 3).
We also ascertained a child with a classic history of AGS
born to nonconsanguineous Scottish parents. He presented
at age 4 mo with developmental delay. Cerebrospinal fluid
examination at age 3 years demonstrated 4 white cells/
mm3 and a raised titre of IFN-a, 6 IU/liter (normal !2 IU/
liter). Magnetic resonance imaging showed demyelina-
tion, and calcification of the basal ganglia was seen on CT
scan. At age 7 years, he was profoundly delayed, with no
meaningful communication, and was fed by gastrostomy
tube. He demonstrated severe spasticity with dystonic pos-
turing and was microcephalic. He had never experienced
seizures. He had several chilblainlike lesions on his toes
and hands and a more generalized patchy mottling of the
skin on all four limbs and over his trunk (fig. 4). These
lesions first developed at age ∼12 mo and, although pres-
ent throughout the year, were significantly worse in the
winter.
Sequencing of TREX1 revealed a heterozygous c.598Gr
A mutation resulting in a DrN substitution at amino acid
residue 200 (fig. 5). Both parents had a homozygous wild-
type genotype at this position. Differentiation of the ma-
ternal and paternal alleles was possible because of a fre-
quently observed CrT SNP at position 531 and subsequent
sequencing of single clones, which allowed us to demon-
strate that the mutation had arisen on the maternal allele.
Genotyping at several loci was consistent with maternity
and paternity. This mutation was not present on 210 Eu-
ropean control alleles, and sequencing of the RNASEH2A,
-B, and -C genes was normal. Using the same method as
above, we measured TREX1 activity in a lymphoblastoid
cell line from the affected child. Interestingly, and in con-
trast to AGS-affected patients with disease resulting from
biallelic TREX1 mutations, we found that TREX1 exonu-
clease activity was within 50%–100% of the activity of a
normal lymphoblastoid control (fig. 3), comparable to the
level seen in cells from unaffected heterozygous parents
of subjects with recessive AGS.6
Our previous analyses of AGS-affected patients with
biallelic TREX1 mutations indicated that AGS at the AGS1
locus results from an abrogation of TREX1 enzyme activ-
ity.6 The TREX1 protein functions as a dimer.17 We doc-
umented an ∼75% reduction of TREX1 activity in FCL-
affected heterozygotes, which is consistent with the het-
erozygous inactivating c.375dupT mutation interfering
with the function of a dimeric molecule. Importantly, our
data show that certain heterozygous mutations lead to
strongly diminished levels of TREX1 activity and that FCL
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Figure 5. Sequence electropherograms illustrating the de novo
c.598GrA TREX1 mutation in the child affected with AGS.
Figure 4. Skin features seen in the child with AGS due to a de
novo heterozygous D200N TREX1 mutation. Ulcerative lesions are
seen at the ends of the toes and fingers, and there is a more
generalized patchy mottling of the skin, seen here on the legs.
can be due to AGS1 mutations. In contrast, enzymatic an-
alysis of the AGS-affected patient we describe here dem-
onstrated close-to-normal activity in a standard exonu-
clease assay. On the basis of homology with TREX2, the
aspartic acid at position 200 in TREX1 represents one of
four residues essential for coordinating two magnesium
ions involved in DNA binding and catalysis.18 It seems
likely that D200N represents a gain-of-function mutation
conferring altered substrate specificity, DNA binding, or
protein-protein interactions; these would not be detected
in the standard TREX1 exonuclease assay.
The observation of heterozygous TREX1 mutations pro-
ducing an enzymatic and clinical phenotype is novel and
relevant. AGS has been considered an autosomal recessive
disorder. Our ongoing genetic studies confirm that this is
true in most cases, but we show here that AGS can also
occur as a result of a de novo mutation in the TREX1 gene,
a finding with obvious implications for genetics counsel-
ing. No major reduction of enzyme activity was observed
in the few TREX1 heterozygotes tested elsewhere,6 and it
has been considered that the parents of patients with AGS
show no overt phenotype. However, a recent survey of
AGS-affected families (Y.J.C., unpublished data) revealed
that 4–40 parents experienced intermittent chilblains fol-
lowing exposure to cold temperatures, although none re-
ported the severe and persistent skin lesions described
here. The explanation for the severity of the lesions seen
in the FCL-affected family we present remains uncertain,
but the observation of nonpenetrance in one sibling is
consistent with the lack of symptoms experienced by most
subjects heterozygous for an AGS mutation. It is of interest
that we know one parent of a patient with AGS who has
SLE, and we suggest that a systematic study of such parents
for biomarkers of SLE is warranted.
In view of the consistent association with elevated levels
of IFN-a,4 we predicted elsewhere that elucidation of the
molecular basis of AGS would provide insights into the
pathogenesis of SLE.8 Our recent finding in AGS-affected
patients of mutations in genes encoding the three non-
allelic components of the RNASEH2 endonuclease protein
complex7 and in the 3′r5′ exonuclease TREX1,6 together
with the observation that TREX1 may be involved in cas-
pase-independent apoptosis,19 adds weight to this predic-
tion, since abnormalities of IFN-a metabolism20 and apop-
tosis21 represent two central themes in the causation of
lupus and other autoimmune diseases. We have now iden-
tified heterozygous TREX1 mutations in a pedigree seg-
regating a monogenic form of FCL. Of note in the context
of AGS, mutations in DNase I are associated with a lupus
phenotype,22 and mice deficient in DNase II accumulate
undigested DNA in macrophages, with consequent IFN-b
up-regulation, and recapitulate the clinical and immuno-
logical phenotype of rheumatoid arthritis.23 We have sug-
gested6 that AGS results from a failure of nuclease activ-
ities, with consequent accumulation of anomalous nucleic
acid species triggering an IFN-a–mediated innate immune
response. For these reasons, further evaluation of the spe-
cific biochemical defect(s) in TREX1 function underlying
dominant AGS and/or FCL should give general insights
into the etiology of inherited lupus.
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